Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Share-based Compensation: 2020-2025

Historic Share-based Compensation for Journey Medical (DERM) over the last 5 years, with Sep 2025 value amounting to $1.9 million.

  • Journey Medical's Share-based Compensation rose 13.05% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year increase of 12.23%. This contributed to the annual value of $6.1 million for FY2024, which is 134.00% up from last year.
  • Journey Medical's Share-based Compensation amounted to $1.9 million in Q3 2025, which was up 38.77% from $1.3 million recorded in Q2 2025.
  • Journey Medical's 5-year Share-based Compensation high stood at $2.4 million for Q4 2021, and its period low was $8,000 during Q3 2021.
  • For the 3-year period, Journey Medical's Share-based Compensation averaged around $1.2 million, with its median value being $1.3 million (2025).
  • Per our database at Business Quant, Journey Medical's Share-based Compensation spiked by 17,875.00% in 2022 and then slumped by 63.26% in 2023.
  • Over the past 5 years, Journey Medical's Share-based Compensation (Quarterly) stood at $2.4 million in 2021, then plummeted by 40.62% to $1.4 million in 2022, then plummeted by 63.26% to $529,000 in 2023, then soared by 160.49% to $1.4 million in 2024, then climbed by 13.05% to $1.9 million in 2025.
  • Its Share-based Compensation was $1.9 million in Q3 2025, compared to $1.3 million in Q2 2025 and $1.3 million in Q1 2025.